[Efficacy of telmisartan in chronic obstructive lung disease wtih arterial hypertension].
The study included evaluation of respiratory function, bronchial conductivity, gas homeostasis, and 24-hour profile of blood pressure (BP) in 15 male patients with chronic obstructive lung disease and I-II stage arterial hypertension prior to and after 2 weeks of therapy with telmisartan. The drug, administered in a dose of 80 mg/day, significantly increased 1 sec forced expiratory volume, peak expiratory flow rate, decreased effective bronchial resistance and CO2 partial pressure in arterial blood. Telmisartan also significantly reduced mean systolic BP (SBP) (p < 0.003) and diastolic BP (DBP) (p < 0.001) during day hours, SBD (p < 0.01) and pulse BP (p < 0.05) during night hours, significantly reduced SBP load (p < 0.02) and DBP load (p < 0.003) during day hours, and SBP load during night hours (p < 0.02).
Pavlishchuk
S A
SA
Bolotova
E V
EV
Porkhanov
V A
VA
D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002940:Circadian Rhythm; D004305:Dose-Response Relationship, Drug; D005540:Forced Expiratory Flow Rates / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000077333:Telmisartan; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan